Alpha Tau Medical Ltd. is a US-listed company in the biotechnology industry. Its financial year ends in December.
Stock price today
Loading chart…
Third-party market data · may be delayed
Fair value per share
Under review: every model's value for Alpha Tau Medical Ltd. is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.
Price vs value
Under review: limited reported history: available models are shown without a Buy/Hold/Sell rating. We'll show the comparison once resolved.
Alpha Tau Medical Ltd. valuation: adjust assumptions and compare models →
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Insiders0 buying, 1 selling0 purchases and 12 sales by directors and officers, last 12 monthsInsider trades
- Funds42 adding, 16 cuttingOf 11 active managers that changed their stake, 8 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
Current signal Results well short of expectations: Reported earnings per share missed the analysts' consensus estimate by 255% in the quarter to 2026-06-30.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
Nothing in Alpha Tau Medical Ltd.'s latest figures clears our strength thresholds.
Things to watch
- Share dilution. Diluted shares rose 15.2% in a year.
- Missing expectations. Earnings per share fell short of the consensus estimate in 4 of the last four quarters.
Latest results
- Earnings per share
- -$0.50 against an average estimate of -$0.14: missed by 254.9%
- Next report
- November 19, 2026; average EPS estimate -$0.15
Price chart
- 1 day-1.8%
- 1 week-0.5%
Loading chart…
Third-party market data · may be delayed
At a glance
Profitability
- EPS (TTM, diluted)
- $-0.53
Growth
- Share count change
- +15.2%
Cash
- Free cash flow (TTM)
- -$32.8M
News & updates
Company announcements, filed results and changes that matter to shareholders.
No recent updates are available for DRTS from the sources we follow. See filings →
The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.
Valuation models
We value Alpha Tau Medical Ltd. as an operating company, with every model that fits that kind of business. Cost of equity 9.9%: the 10-year Treasury yield (4.9%) plus a beta of 1.1 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. | ~$0.4 ~$0.5–$1.7 | Left out: out of range vs price (0.03x) |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. | — | Combined value withheld. Review the individual models and their assumptions. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Alpha Tau Medical Ltd. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Next results: November 19, 2026, after the close. Analysts expect revenue of $324330 and EPS of −$0.15 (range −$0.16 to −$0.13) for the quarter.
Analysts' consensus
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$0.96 | −80% | $944330 | 0% |
| Next | −$0.53 | +44% | $13m | +1236% |
How the EPS forecast has moved
The consensus EPS forecast for the current fiscal year is +45.1% on 90 days ago. In the last 30 days, 1 analyst raised Alpha Tau Medical Ltd.'s forecast and 4 cut it.
Average of analysts' published estimates (third-party data).
View chart data
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | −$0.66 | −$0.51 |
| 60 days ago | −$0.88 | −$0.53 |
| 30 days ago | −$0.96 | −$0.53 |
| 7 days ago | −$0.96 | −$0.53 |
| Now | −$0.96 | −$0.53 |
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | −$0.14 | −$0.50 | −254.9% |
| Mar 2026 | −$0.12 | −$0.26 | −110.4% |
| Dec 2025 | −$0.12 | −$0.14 | −13.4% |
| Sept 2025 | −$0.12 | −$0.14 | −21.4% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- 5.3% of tradable shares
- Days to cover
- 7.22 at average volume
- Short interest, 1 month
- −1% to October 15, 2026
- Held by institutions
- 9% of shares
- Held by insiders
- 30.5% of shares
- Employees
- 121 full time
Share-price performance
Market data may be delayedPrice behaviour
- 52-week range
- Not enough history
- From 52-week high
- —
- vs 50-day average
- —
- vs 200-day average
- —
- Volatility (1 year)
- —
- Beta vs S&P 500
- —
Fundamentals
Financial health
- Short-term assets cover short-term liabilities $78m of assets due within a year against $11m of liabilities due within a year.
- Short-term assets cover long-term liabilities $78m short-term assets against $18m of longer-dated liabilities.
- More cash than debt Cash or debt not separately reported. Not assessable.
- Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
- Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
- A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
- Operating profit covers interest at least five times over Operating income of −$42m against $347,000 of interest.
Dividends, buybacks and capital spending
- Diluted share count
- +15.2%
- year over year
Who owns it
Funds buying and selling- Reported value
- $100M
- Institutions reporting
- 73
- Shares held vs prior quarter
- ▲ 96.2%
- Positions opened / closed
- 24 / 6
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Gem Investment Advisors, LLC | $18M | 1.4M | 18.0% | ▲ 1161.2% |
| Hightower Advisors, LLC | $11M | 875K | 11.0% | 0.0% |
| Boothbay Fund Management, LLC | $9.7M | 773K | 9.7% | New |
| Aquamarine Financial (Cayman) Ltd | $9.1M | 722K | 9.1% | 0.0% |
| Pier Capital, LLC | $8.7M | 692K | 8.7% | New |
| UBS Group AG | $8.1M | 642K | 8.1% | ▲ 124.0% |
| Apella Capital, LLC | $4.9M | 382K | 4.9% | 0.0% |
| ARK Investment Management LLC | $3.5M | 277K | 3.5% | ▼ 5.2% |
| Polen Capital Management LLC | $2.8M | 221K | 2.8% | New |
| Focus Partners Wealth | $2.3M | 185K | 2.3% | ▲ 472.5% |
| Mariner, LLC | $2.1M | 167K | 2.1% | ▲ 14.1% |
| Daytona Street Capital LLC | $1.8M | 146K | 1.8% | 0.0% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Alpha Tau Medical Ltd.'s complete shareholder register. Values are as reported by the filers .
Insider trading activity
Full insider history and chart| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Levy Raphi Chief Financial Officer | August 21, 2026 | Sell pre-set plan | 2,871 | $15.00 | $43,065 |
| Levy Raphi Chief Financial Officer | August 11, 2026 | Sell pre-set plan | 17,730 | $14.00 | $248,220 |
| Levy Raphi Chief Financial Officer | July 6, 2026 | Sell pre-set plan | 2,270 | $14.00 | $31,780 |
| Levy Raphi Chief Financial Officer | July 2, 2026 | Sell pre-set plan | 17,873 | $13.00 | $232,349 |
| Levy Raphi Chief Financial Officer | July 1, 2026 | Sell pre-set plan | 2,127 | $13.02 | $27,694 |
| Levy Raphi Chief Financial Officer | June 30, 2026 | Sell pre-set plan | 20,000 | $12.00 | $240,000 |
| Levy Raphi Chief Financial Officer | June 25, 2026 | Sell pre-set plan | 15,778 | $11.00 | $173,558 |
| Levy Raphi Chief Financial Officer | June 25, 2026 | Sell pre-set plan | 4,222 | $11.00 | $46,442 |
| Levy Raphi Chief Financial Officer | June 23, 2026 | Sell pre-set plan | 2,500 | $10.00 | $25,000 |
| Levy Raphi Chief Financial Officer | June 23, 2026 | Sell pre-set plan | 15,000 | $9.47 | $142,050 |
| Levy Raphi Chief Financial Officer | June 3, 2026 | Sell | 17,500 | $10.90 | $190,750 |
| Levy Raphi Chief Financial Officer | June 3, 2026 | Sell | 15,000 | $10.76 | $161,400 |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Results announcements
Recent SEC filings
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Alpha Tau Medical Ltd. in brief
- What does Alpha Tau Medical Ltd. do?
- Alpha Tau Medical Ltd. is a US-listed company in the biotechnology industry. Its financial year ends in December.
- What is Alpha Tau Medical Ltd.'s stock ticker?
- Alpha Tau Medical Ltd. trades under the ticker DRTS on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Who are Alpha Tau Medical Ltd.'s largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are Gem Investment Advisors, LLC, Hightower Advisors, LLC and Boothbay Fund Management, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
- Are insiders buying or selling Alpha Tau Medical Ltd. stock?
- Over the last 12 months, Alpha Tau Medical Ltd.'s directors and officers reported 0 open-market purchases and 12 sales on Form 4. The insider trading page charts every trade.
- When is Alpha Tau Medical Ltd.'s next earnings date?
- Around November 19, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Alpha Tau Medical Ltd. announces its own schedule.
Follow research on Alpha Tau Medical Ltd.
New research on the companies we cover arrives in the weekly email. Free, one email a week.